Approach to asymptomatic paraesophageal hernia: watchful waiting or elective laparoscopic hernia repair?
- 436 Downloads
There is no consensus on whether asymptomatic paraesophageal hernia (PEH) should be operated. Some argue that surgery is necessary prophylaxis against potentially catastrophic consequences of acute complications in untreated PEH. Others reason that the acute complications are rare and emergent operations have relatively low mortality. In the laparoscopic era, elective operations have become safer and less morbid. However, recent studies report high incidence of recurrent hernia, some of which affect quality of life and require further interventions. In light of these new findings, we investigated whether asymptomatic PEH should receive elective laparoscopic hernia repair (ELHR) or watchful waiting (WW).
A Markov Monte Carlo microsimulation decision analysis model followed a hypothetical cohort of asymptomatic PEH patients who have predominantly female gender and normally distributed mean age of 62.5 years for the lifetime. Accrued health benefits expressed in quality-adjusted life months (QALM) were compared between two strategies: WW and ELHR. Two-dimensional simulations were performed to account for uncertainties in the model. Deterministic sensitivity analyses were performed to test key assumptions.
After considering both individual- and parameter-level uncertainties in the two-dimensional simulations, WW was the superior strategy in 82% of the simulations, accumulating mean 5 QALM more than ELHR (168 vs. 163). Our model was robust to deterministic sensitivity analyses and was internally validated, which supported the validity of our results.
Patients with asymptomatic PEH are more likely to achieve greater health outcomes if they undergo WW as initial treatment than ELHR.
KeywordsHiatal hernia Paraesophageal hernia Laparoscopic surgery Decision analysis Markov model
Compliance with ethical standards
Dr. Grantcharov received grants from Ethicon Canada, Medtronic Canada, Olympus Canada, Takeda Canada, and Baxter Canada and owns intellectual properties from Surgical Safety Technologies Inc. Drs. Jung, Naimark, and Behman have no conflicts of interest or financial ties to disclose.
- 16.Oelschlager BK, Pellegrini CA, Hunter JG, Brunt ML, Soper NJ, Sheppard BC, Polissar NL, Neradilek MB, Mitsumori LM, Rohrmann CA, Swanstrom LL (2011) Biologic prosthesis to prevent recurrence after laparoscopic paraesophageal hernia repair: long-term follow-up from a multicenter, prospective, randomized trial. J Am Coll Surg 213:461–468CrossRefPubMedGoogle Scholar
- 17.Oelschlager BK, Pellegrini CA, Hunter J, Soper N, Brunt M, Sheppard B, Jobe B, Polissar N, Mitsumori L, Nelson J, Swanstrom L (2006) Biologic prosthesis reduces recurrence after laparoscopic paraesophageal hernia repair: a multicenter, prospective, randomized trial. Ann Surg 244:481–490PubMedPubMedCentralGoogle Scholar
- 18.Hashemi M, Peters JH, DeMeester TR, Huprich JE, Quek M, Hagen JA, Crookes PF, Theisen J, DeMeester SR, Sillin LF, Bremner CG (2000) Laparoscopic repair of large type III hiatal hernia: objective followup reveals high recurrence rate. J Am Coll Surg 190:553–560 (discussion 560–551)CrossRefPubMedGoogle Scholar
- 32.Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibanes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M (2009) The Clavien–Dindo classification of surgical complications: five-year experience. Ann Surg 250:187–196CrossRefPubMedGoogle Scholar
- 35.England TRCoSo (2012) Access all ages. Assessing the impact of age on access to surgical treatment. Latimer Trend & Company Ltd, PlymouthGoogle Scholar
- 36.Arias E (2012) United States Life Tables, 2008. National vital statistics reports: National Center for Health Statistics 61Google Scholar
- 39.Comay D, Adam V, da Silveira EB, Kennedy W, Mayrand S, Barkun AN (2008) The Stretta procedure versus proton pump inhibitors and laparoscopic Nissen fundoplication in the management of gastroesophageal reflux disease: a cost-effectiveness analysis. Can J Gastroenterol 22:552–558CrossRefPubMedPubMedCentralGoogle Scholar